Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isa-RVD in newly diagnosed multiple myeloma
NCT05123131Phase 2Active, not recruiting
- Sponsor
- Cancer Trials Ireland
- Start
- Apr 2022
- Primary completion
- Jun 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of isatuximab in multiple myeloma (MM), sponsored by Cancer Trials Ireland. Primary endpoints: Stringent Complete Response Rate and Very Good Partial Response Rate. Started Apr 2022; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05123131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05123131.